as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹939.55
Change
+5.3 (0.57%)
Open
₹930.0
Prev. Close
₹934.25
Day High
₹962.0
Day Low
₹915.45
Volume Analysis
Traded
675,198
Delivered
172,314
Delivery %
25.52%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹957.0)
- •Strong operating margin (22.0%)
Weaknesses (2)
- •Low return on equity (8.59%)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,009.1 | ₹985.55 | ₹962.55 | ₹939.0 | ₹916.0 | ₹892.45 | ₹869.45 |
| Fibonacci | ₹985.55 | ₹967.77 | ₹956.78 | ₹939.0 | ₹921.22 | ₹910.23 | ₹892.45 |
| Camarilla | ₹952.35 | ₹948.08 | ₹943.82 | ₹939.0 | ₹935.28 | ₹931.02 | ₹926.75 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+26.25%
1 Week
+11.0%
1 Month
+11.76%
3 Months
+38.16%
6 Months
+47.95%
1 Year
+14.02%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹318.52
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.23%
Net margin 10.82% × asset turnover 0.52x × equity multiplier 1.64x
Company Overview
Sector
Healthcare
Market Cap
₹8,472 Cr
P/E (TTM)
39.4
ROE
8.59%
Book Value
₹234.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Aarti Pharmalabs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 54/100. The strongest factor is Financial Strength (97/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹957.0); strong operating margin (22.0%); low return on equity (8.59%); promoter holding is falling.
TopFund Score — Fundamentals Quality
54/100 — AverageData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 3.99 times its book value
- −Company has a low return on equity of 11.9% over last 3 years.
- −Promoter holding has decreased over last 3 years: -3.12%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Rajendra Gogri ceased as director; Rashesh Gogri becomes MD and Hetal Gogri Gala becomes WTD from Oct 1, 2026.
AGM shareholders approved ₹2 final dividend and management changes, including Rajendra Gogri exit and new MD effective Oct 1, 2026.
Investor Presentation made at the 7th Annual General Meeting
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses + | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 19.0% | 20.0% | 21.0% | 23.0% | 17.0% | 20.0% | 24.0% | 26.0% | 24.0% | 18.0% | 24.0% | 19.0% | 25.0% |
| Other Income + | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| Profit before tax | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 26.0% | 23.0% | 29.0% | 32.0% | 25.0% | 24.0% | 26.0% | 23.0% | 24.0% | 28.0% | 24.0% | 25.0% | 25.0% |
| Net Profit + | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS in Rs | 5 | 6 | 6 | 7 | 6 | 6 | 8 | 10 | 5 | 3 | 5 | 7 | 8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses + | 0 | 993 | 1,603 | 1,467 | 1,649 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | — | 17.0% | 18.0% | 21.0% | 22.0% | 20.0% | 22.0% |
| Other Income + | 0 | 3 | 2 | 5 | 8 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | — | 21.0% | 26.0% | 28.0% | 24.0% | 25.0% | — |
| Net Profit + | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS in Rs | — | — | 21 | 24 | 30 | 19 | 24 |
| Dividend Payout % | — | 0.0% | 9.0% | 13.0% | 17.0% | 18.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Reserves | 0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings + | 0 | 338 | 215 | 285 | 413 | 754 |
| Other Liabilities + | 0 | 315 | 470 | 540 | 499 | 603 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Fixed Assets + | 0 | 782 | 926 | 1,033 | 1,137 | 1,437 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 393 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other Assets + | 0 | 1,038 | 1,130 | 1,305 | 1,315 | 1,457 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Equity Capital | 0 | 0 | 45 | 45 | 45 | 45 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -44 | 250 | 216 | 330 | 262 |
| Cash from Investing Activity + | 0 | -139 | -158 | -215 | -412 | -431 |
| Cash from Financing Activity + | 0 | 260 | -163 | 10 | 65 | 171 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 | 2 |
| CFO/OP | — | -11 | 91 | 71 | 85 | 84 |
| Free Cash Flow | 0 | -185 | 130 | 18 | -114 | -186 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 34.73% | 35.45% | 35.24% | 35.0% | 35.17% | 36.33% | 40.81% | 41.12% | 42.12% | 41.54% | 41.1% | 41.74% |
| Promoters | 46.3% | 46.46% | 46.46% | 46.46% | 46.1% | 44.65% | 44.29% | 43.72% | 42.88% | 43.1% | 43.08% | 42.86% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 8.45% | 8.17% | 8.33% | 7.07% | 7.38% | 8.64% | 7.36% | 7.34% | 8.02% | 7.69% | 8.39% | 8.17% |
| DII | 10.51% | 9.91% | 9.97% | 11.47% | 11.35% | 10.36% | 7.53% | 7.8% | 6.95% | 7.66% | 7.4% | 7.22% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Aarti Pharmalabs Limited (this stock) | 8,472 | 39.4 | 3.99 | 8.59% |
| Jupiter Life Line Hosp L | 8,706 | 45.6 | 5.65 | 13.1% |
| Thyrocare Tech Ltd | 9,022 | 49.9 | 15.41 | 28.4% |
| Bliss Gvs Pharma Ltd | 7,486 | 54.4 | 6.23 | 11.8% |
| Suven Life Sciences Ltd | 9,466 | — | 14.96 | -81.5% |
| Innova Captab Limited | 7,402 | 48.1 | 6.78 | 13.7% |
| Sanofi India Limited | 7,232 | 16.4 | 8.4 | 47.1% |
Which Mutual Funds Hold Aarti Pharmalabs Limited?
Frequently Asked Questions about Aarti Pharmalabs Limited
Aarti Pharmalabs Limited (AARTIPHARM) closed at ₹939.55 on NSE on 25 September 2026, up 5.3 (0.57%) from the previous close.
Aarti Pharmalabs Limited trades on the NSE (National Stock Exchange of India) under the symbol AARTIPHARM.
Aarti Pharmalabs Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 39.4.
Aarti Pharmalabs Limited has a dividend yield of 0.37%.
Aarti Pharmalabs Limited's 52-week high is ₹957.0 and its 52-week low is ₹584.0.
Aarti Pharmalabs Limited has a market capitalisation of ₹8,472 crore.
Aarti Pharmalabs Limited has a TopFund Quality Score of 54/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Aarti Pharmalabs Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.